On “Composition, Quality Control, and Labeling of Plasma-Derived Products for the Treatment of von Willebrand Disease” (Semin Thromb Hemost 2006;32: 529-536)

REFERENCES

• 1 Mazurier C. Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease.  Semin Thromb Hemost. 2006;  32 529-536
• 2 Committee for Proprietary Medicinal Products (CPMP) .Note for guidance on plasma-derived medicinal products. CPMP/BWP/269/95 rev.3 January 25, 2001
• 3 Stadler M, Gruber G, Kannicht C et al.. Characterisation of a novel high-purity, double virus inactivated von Willebrand factor and factor VIII concentrate (Wilate^® .  Biologicals. 2006;  34 281-288